The University of Miami received a $1,131,820 five-year Project Grant award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) to conduct a study titled "Symptomatic Toxicities & Quality of Life Among Diverse Individuals Receiving Immune Checkpoint Inhibitors for Metastatic Cancer." The key objectives are to: 1) characterize toxicities and health-related quality of life over time among diverse patients receiving checkpoint inhibitors for metastatic cancer, and identify patient profiles at elevated risk; 2) examine modifiable behavioral, psychosocial, and care delivery factors associated with toxicities and quality of life; and 3) determine whether toxicities and quality of life predict clinical endpoints like treatment modification, discontinuation, progression, and healthcare utilization. The research aims to generate critical knowledge to inform interventions that can improve the safety and tolerability of checkpoint inhibitor immunotherapies for diverse cancer patients.